LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | GSK1904529A | 1.11 | uM | LJP6 | 72 | hr | 1235 | 1904 | 4056 | 0.4695 | 0.2870 |
| MCF7 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1945 | 4056 | 0.4793 | 0.3020 |
| MCF7 | GSK1904529A | 10 | uM | LJP6 | 72 | hr | 1235 | 1742 | 4056 | 0.4291 | 0.2201 |
| MCF7 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 3243 | 4267 | 0.7593 | 0.7122 |
| MCF7 | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3268 | 4267 | 0.7670 | 0.7244 |
| MCF7 | Linsitinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 2401 | 4267 | 0.5632 | 0.4504 |
| MCF7 | Linsitinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2251 | 4267 | 0.5279 | 0.3984 |
| MCF7 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 2187 | 4267 | 0.5122 | 0.3740 |
| MCF7 | Linsitinib | 10 | uM | LJP5 | 72 | hr | 1235 | 1868 | 4267 | 0.4376 | 0.2591 |
| MCF7 | Ruxolitinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 3891 | 4267 | 0.9125 | 0.9001 |
| MCF7 | Ruxolitinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3957 | 4267 | 0.9270 | 0.9166 |
| MCF7 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 3973 | 4267 | 0.9305 | 0.9195 |
| MCF7 | Ruxolitinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4302 | 4267 | 1.0077 | 1.0077 |
| MCF7 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4398 | 4267 | 1.0299 | 1.0321 |
| MCF7 | Ruxolitinib | 10 | uM | LJP5 | 72 | hr | 1235 | 3184 | 4267 | 0.7457 | 0.6961 |
| MCF7 | Momelotinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 3936 | 4267 | 0.9212 | 0.9070 |
| MCF7 | Momelotinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3478 | 4267 | 0.8150 | 0.7837 |
| MCF7 | Momelotinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 3297 | 4267 | 0.7735 | 0.7326 |
| MCF7 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2804 | 4267 | 0.6573 | 0.5808 |
| MCF7 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1785 | 4267 | 0.4184 | 0.2277 |
| MCF7 | Momelotinib | 10 | uM | LJP5 | 72 | hr | 1235 | 1411 | 4267 | 0.3310 | 0.0775 |
| MCF7 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4587 | 4267 | 1.0724 | 1.0751 |
| MCF7 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4228 | 4267 | 0.9906 | 0.9892 |
| MCF7 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 3512 | 4267 | 0.8238 | 0.7932 |
| MCF7 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4831 | 4267 | 1.1327 | 1.1447 |